Page 3 - Nasdaq Itrm News Today

Iterum Therapeutics (NASDAQ:ITRM – Get Rating) posted its quarterly earnings results on Monday. The company reported ($0.02) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.04) by $0.02, MarketWatch Earnings reports. During the same period in the prior year, the company earned ($0.11) earnings per share. Shares of ITRM stock opened […]

Iterum Therapeutics (NASDAQ:ITRM – Get Rating) and I-Mab (NASDAQ:IMAB – Get Rating) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, risk, institutional ownership, valuation, dividends, earnings and analyst recommendations. Profitability This table compares Iterum Therapeutics and I-Mab’s net margins, […]

Iterum Therapeutics plc (NASDAQ:ITRM – Get Rating) CFO Judith M. Matthews sold 47,132 shares of Iterum Therapeutics stock in a transaction that occurred on Monday, March 14th. The shares were sold at an average price of $0.38, for a total transaction of $17,910.16. The sale was disclosed in a filing with the Securities & Exchange […]

Iterum Therapeutics plc Announces $35.0 Million Registered Direct Offering of Ordinary Shares Priced At-the-Market under Nasdaq Rules February 09, 2021 23:58 ET | Source: Iterum Therapeutics plc Iterum Therapeutics plc Dublin 2, IRELAND DUBLIN, Ireland and CHICAGO, Feb. 09, 2021 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiot...